Trial Profile
To evaluate the efficacy of Eltrombopag in patients with immune thrombocytopenia purpura (ITP) in severe disease or as bridging therapy for invasive procedures or chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Aug 2017
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- 01 Sep 2016 New trial record